The Pan American Journal of Public Health published a letter from Professor Erika Lietzan, in which she responds to an article about Colombia’s pathways for approval of biosimilar biologics. A 2014 presidential decree in Colombia allowed for three pathways to market for biologics, and the earlier article, written by the country’s Minister of Health and Social Protection and his colleagues,…